Good MorningEquity markets pulled back on Thursday following a hotter-than-expected inflation report. The PPI index advanced compared to last year, accelerating at the headline level and sustaining a 3.5% at the core, underpinning an expectation for consumer inflation to run hot in December. The takeaway is that FOMC has less need to lower interest rates than ever, and it may surprise the market next week when it meets. With CPI and PPI running hot, they will be hard-pressed to justify a cut, more so a dovish posture for 2025. Investors should expect the Fed to indicate a pause in the lowering cycle at the very least.
The S&P 500 fell about half a percent at the session's low, hovering within a tight two-week trading range. The market is consolidating and digesting the economic data to decide which direction to take next. As big a risk as inflation and higher-for-longer interest rates are, the underlying cause is healthy economic conditions and a resilient consumer, which is no reason for a sell-off. In this scenario, the market's long-term trajectory remains upward regardless of the near-term market movement over the coming weeks. Featured: WARNING: “Buffett Indicator” flashing for first time in 50 years (Behind the Markets) 
|
Markets | | | The WallStreetBets, also known as r/wallstreetbets or WSB, is a subreddit community that has transformed into a powerful force capable of disrupting traditional stock market dynamics.
Known for its irreverent humor and often-contrarian approach, WSB gained notoriety for its role in the “meme ... Read the Full Story |
|
From Our PartnersNow is the time to consider a time-tested asset favored by conservative investors for navigating market volatility and building long-term security. Whether the results lean toward continuity or change, this asset remains a stable cornerstone for safeguarding wealth and driving growth.
By following the link, you're choosing to opt in to receive insightful updates from Wealth Creation Investing + 2 free bonus subscriptions! Your privacy is important to us. You can unsubscribe anytime. See our privacy policy for details. | | | | [Download the Free Guide Now] to explore the potential of this strategy and discover what may be missing from your financial plan. |
|
Markets | | |
More and more market participants are becoming aware of the quantum computing trends popping up in the technology sector right now. What used to be the hot topic of artificial intelligence has now shifted into the next frontier for the industry. The capabilities and profit potential aren’t... Read the Full Story |
|
Markets | | |
How business used to be done has changed, and the share of transactions, marketing, and sales done in the new digitized economy is growing. Gone are the days of door-to-door salesmanship, unless it is to sell a power-washing or solar panel service, which has several limitations as far as efficienc... Read the Full Story |
|
|
Markets | | | Major stock indexes on Wall Street drifted to a mixed finish Friday, capping a rare bumpy week for the market.The S&P 500 ended essentially flat, down less than 0.1%, after wavering between tiny gains and losses most of the day. The benchmark index posted a loss for the week, its first after thr... Read the Full Story |
|
Markets | | |
According to several indicators—including a robust labor market and tamed inflation figures—the U.S. economy heads into 2025 with strong tailwinds. Many of the securities that have been primary beneficiaries of this economic well-being are large-cap (or even mega-cap) titans in the tec... Read the Full Story |
|
From Our PartnersDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years?
If so, you don't want to miss this... | | | | Watch this short video |
|
Markets | | | A quarterly survey by Japan’s central bank shows business sentiment has improved slightly, especially in major heavy industries such as automaking, fossil fuels and machinery, while services industries were less upbeat. The survey released Friday by the Bank of Japan, called the tankan, might influe... Read the Full Story |
|
Markets | | | Chinese leaders met this week to plot economic policy for the coming year, sketching out plans to raise government spending and relax Beijing’s monetary policy to encourage more investment and consumer spending. Leaders of the ruling Communist Party wrapped up their two-day Central Economic Work Con... Read the Full Story |
|
Markets | | | Moldova’s parliament has voted in favor of imposing a state of emergency in the energy sector over fears that Russia could leave the European Union candidate country without sufficient natural gas supplies this winter Read the Full Story |
|
Markets | | | The Consumer Financial Protection Bureau said Thursday it's capping overdraft fees at $5 with a rule set to take effect in October 2025, if it isn't overturned by Congress or altered under a Trump administration Read the Full Story |
|
Markets | | |
In 2024, it seems to be a year of the haves and the have-nots in the cybersecurity industry. Bigger firms have tended to get bigger, while smaller ones have tended to lose value. Among eight large-cap cybersecurity stocks, including Palo Alto Networks (NASDAQ: PANW), the average 2024 return i... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. | | View Today's Stock Pick |
|
